



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/572,826	First Named Inventor: Liu
371 Filing Date: March 22, 2006	Attorney Docket No.: 101193-1P US
Examiner: Unknown	Group Art Unit :
Customer No.: 22466	Confirmation No.: 3323
Title: Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof	

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

The English translation of foreign patent document reference No. 17, (EP patent number 0597304) is provided according to 37 CFR §1.98(a)(3) by the virtue of providing its U.S. equivalent, U.S. patent number 5,482,956, cited as Ref. No. 1.

In addition, Applicant(s) wish to call to the Examiner's attention the following commonly-owned, co-pending patent applications:

- 1) U.S. Application Serial No. 10/572929, filed as a PCT application on September 24, 2004;
- 2) U.S. Application Serial No. 10/572825, filed as a PCT application on September 24, 2004;
- 3) U.S. Application Serial No. 10/573054, filed as a PCT application on September 24, 2004; and
- 4) U.S. Application Serial No. 11/419603, filed on May 22, 2006.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. §1.491 in an international application.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101193-1P US.

Respectfully submitted,
/Jianzhong SHEN, Reg.#48076/

Name: Jianzhong Shen
Dated: June 20, 2006
Reg. No.: 48,076
Phone No.: 302-886-8854
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437